Latham & Watkins LLP advised the syndicate banks on MorphoSys’ increase of its current share capital from €34,231,943 to €37,655,137 through a full utilization of its authorized capital 2023-II. Shareholders’ pre-emptive rights were excluded. The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (New Shares) have been placed with institutional investors at a placement price of €30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately €102.7 million.
The New Shares shall be admitted to trading without a prospectus and included in the existing quotation for the Company’s shares in the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange and carry full dividend rights as from January 1, 2023. The delivery and the first day of trading of the New Shares is expected to occur on or around December 19, 2023.
The Latham team was led by Frankfurt partners Oliver Seiler and David Rath, with New York partners Nathan Ajiashvili and Alison Haggerty and associates Camilla Kehler-Weiß, Alexandre Maturana, and Angel Marcial.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
